A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF)
Phase of Trial: Phase I
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions
- Acronyms HARMONY
- Sponsors Novartis Pharmaceuticals
- 06 Mar 2019 Status changed from completed to discontinued.
- 13 Nov 2017 Status changed from active, no longer recruiting to completed.
- 17 Jul 2017 Planned End Date changed from 1 Dec 2018 to 1 Sep 2017.